申请人:Sato Michitaka
公开号:US20070197551A1
公开(公告)日:2007-08-23
This invention provides pyrimidine derivatives represented by a formula,
in the formula, ring A stands for carbocyclic group or heterocyclic group,
X
1
stands for hydrogen, lower alkyl, amino, etc.,
X
2
stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and
Ar stands for a group of the following formula,
or a salt thereof, which concurrently exhibit 5-HT
1A
agonistic activity and 5-HT
3
antagonistic activity and are useful for therapy and treatments of diseases such as IBS.
The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT
1A
agonistic activity and 5-HT
3
antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT
3
antagonistic agent which concurrently exhibits 5-HT
1A
agonistic activity, or administering 5-HT
1A
agonistic agent and 5-HT
3
antagonistic agent simultaneously, in sequence or at an interval.
本发明提供了由下式表示的嘧啶衍生物,其中,环A代表碳环基团或杂环基团,X1代表氢、低碳基、氨基等,X2代表氢或低碳基,Y代表直接键或硫或氮,n代表0-4的整数,Ar代表以下式的基团,或其盐,同时表现出5-HT1A激动活性和5-HT3拮抗活性,并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法,其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性,包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂,或同时给予5-HT1A激动剂和5-HT3拮抗剂,按顺序或间隔给予。